MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced new preclinical data showing the positive combined effects of its lead compound, buntanetap, with the GLP-1 agonist dulaglutide (Trulicity ...

Women who quit smoking and were treated with the GLP-1 receptor agonist dulaglutide were less likely to experience substantial weight gain compared with those who received placebo, according to ...

Switching to tirzepatide also led to a weight loss of 10.5 kg (23.1 lb) compared with 3.6 kg (7.9 lb) with the higher dulaglutide dose (P<0.001), according to Liana Billings, MD, of the University ...

RESEARCH DESIGN AND METHODS: This 52-week, multicenter, parallel-arm study (primary end point: 26 weeks) randomized patients (2:2:2:1) to dulaglutide 1.5mg, dulaglutide 0.75mg, exenatide 10g, or ...

Compared with a combination of insulin glargine, metformin and glimepiride, once-weekly dulaglutide demonstrated superiority and noninferiority as a type 2 diabetes therapy with two different ...

Glomerular hyperfiltration and proteinuria were reduced among youth with type 2 diabetes who received dulaglutide compared with placebo.

Dulaglutide was FDA approved in 2014 for the treatment of adults with type 2 diabetes. Developer Eli Lilly announced in 2020 that the agent gained an indication to reduce the risk of major adverse ...

Matthew Reaney, from ERT in Peterborough, U.K., and colleagues compared satisfaction among patients with type 2 diabetes receiving once-weekly dulaglutide (1.5 and 0.75mg) with those receiving ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. Bose, Priyom. (2024, March 08). Diabetes drug dulaglutide may reduce symptoms of depression.

Dulaglutide was started at 1.5 mg once-weekly and continued at that dose for the 26-week treatment period. Liraglutide was initiated according to labeling, and started at 0.6 mg/day in Week 1 and ...